PMCB - PharmaCyte Biotech, Inc.

Other OTC - Other OTC Delayed Price. Currency in USD
0.0675
-0.0024 (-3.4335%)
As of 10:59AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.0699
Open0.0680
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0660 - 0.0700
52 Week Range0.0300 - 0.1200
Volume772,458
Avg. Volume2,481,301
Market Cap65.723M
Beta2.51
PE Ratio (TTM)N/A
EPS (TTM)-0.0110
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Business Wire17 days ago

    PharmaCyte Announces Completion of Preparatory Work and Commencement of Testing by Eurofins of Cells from Its Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the steps necessary for the testing of cells from its Master Cell Bank have been completed by Eurofins Lancaster Laboratories and that testing began last month.

  • Business Wirelast month

    PharmaCyte Announces Completion of Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that the Master Cell Bank of cells that will be used in its upcoming trial in patients with locally advanced non-metastatic and inoperable pancreatic cancer has been fully populated....

  • Business Wire2 months ago

    PharmaCyte Biotech Meets with Oncology Advisory Board

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it recently met with its Oncology Advisory Board, which was formed to assist in optimizing and finalizing the clinical protocol and other clinical trial-related matters ...

  • Business Wire3 months ago

    PharmaCyte Biotech Announces Production of Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that the production of the cells necessary to prepare the Master Cell Bank has started.

  • Business Wire3 months ago

    PharmaCyte Biotech Announces Successful Completion of Cell Testing for Production of Master Cell Bank

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today reported that Eurofins Lancaster Laboratories, a leading Contract Manufacturing Organization that PharmaCyte selected to prepare its Master Cell Bank , has successfully completed its ...

  • Business Wire3 months ago

    British Columbia Securities Commission Revokes Cease Trade Order on PharmaCyte Biotech Securities

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it is providing a summary overview, corporate history and status report to address a regulatory compliance request from the British Columbia Securities Commission which, ...

  • Business Wire4 months ago

    PharmaCyte Biotech Appoints Dr. Raymond Tong to Board of Directors

    PharmaCyte Biotech, Inc. , a clinical stage biotechnology company focused on developing targeted therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced the appointment of Dr.